Clinical Trials Logo

Clinical Trial Summary

Primary Objective:

To evaluate the impact of PCV7 vaccination on NP carriage rate of vaccine serotypes and serotype distribution

Secondary Objective:

To evaluate the impact of PCV7 vaccination on NP carriage of antibiotic resistant pneumococci and serotype distribution.


Clinical Trial Description

Under the Social Welfare Vaccination Program, the Taipei City Government will vaccinate approximately 5,000 children residing in the city of Taipei between 2 and 5 years of age during the months of November 2006 to April 2007 with one dose of PCV7.

To gather baseline data on serotype distribution and antibiotic resistance of nasopharyngeal (NP) carriage isolates in this population and measure vaccine impact on NP carriage, the Taipei city government requires the evaluation of the vaccination program through the detection of Streptococcus pneumoniae NP carriage rate pre and post vaccination in a convenience sample of approximately 1000 children. This number complies with the Taipei city government request for the inclusion of 250 children.

Streptococcus pneumoniae is a major cause of bacterial otitis media, pneumonia, sepsis, bacteraemia, and meningitis among infants worldwide.

The main reservoir of pneumococci is the human nasopharynx. The mean age of first acquisition is 6 months and carriage rates peak in the preschool age group. The organisms have pilli on their surface to assist in adhering to nasopharyngeal mucosal receptors. Streptococcus pneumoniae is part of the normal flora in colonized individuals, but the organism has the ability to cause disease by invading neighboring tissues, and potentially spreading into the bloodstream and other sites, causing invasive pneumococcal disease, such as bacteremia, sepsis and meningitis. The rate of NP carriage for Streptococcus pneumoniae in Taiwan (1998-99) was estimated to be 19.9 % overall for children 1-14 years and 27.1 % for those 2-5 years. A more recent study by Lauderdale et al. found a carriage rate of 41 % in children attending a kindergarten program in Taiwan where a 5 year old was diagnosed with streptococcus meningitis.

Prevnar® has shown a high degree of efficacy in the prevention of invasive pneumococcal disease in children. In addition, PCV7 has been shown to decrease NP carriage of serotypes included in the vaccine (VST). Since NP carriage is a prerequisite for transmission of Streptococcus pneumoniae, decrease in NP carriage of VSTs in children has resulted in decreased transmission to their contacts and an indirect effect (herd effect) on invasive pneumococcal disease. Since the majority of antibiotic resistant strains are VST, PCV7 immunization has decreased antibiotic resistance in invasive pneumococcal disease for both those immunized and their contacts. However, after PCV7 vaccination overall pneumococcal NP carriage rates do not change, since Streptococcus pneumoniae serotypes not included in the vaccine (NVST) replace the VSTs. Although in the nasopharynx there is an almost complete replacement by NVST, these serotypes may have less ability to cause invasive disease, since disease with NVST has been observed but to a much lower magnitude than disease prior to PCV7 vaccination.

Thus, the expected outcome of a successful PCV7 vaccination program on NP carriage is a decrease in carriage of VST with an increase in NVST and thus, a stable overall Streptococcus pneumoniae carriage rate. ;


Study Design

Time Perspective: Prospective


Related Conditions & MeSH terms


NCT number NCT00488371
Study type Observational
Source Wyeth is now a wholly owned subsidiary of Pfizer
Contact
Status Completed
Phase Phase 4
Start date November 2006
Completion date April 2007

See also
  Status Clinical Trial Phase
Completed NCT02201030 - Immunogenicity and Safety Study of NBP606 in Healthy Infants Phase 3
Completed NCT02787863 - Clinical and Immunological Efficiency of Bacterial Vaccines at Adult Patients With Bronchopulmonary Pathology Phase 4
Completed NCT04031846 - Safety, Tolerability, and Immunogenicity of V114 in Healthy Infants (V114-025) Phase 3
Recruiting NCT05920499 - The Effect of AUDIT and Feedback on Pneumococcal Vaccination Coverage N/A
Completed NCT01215175 - Safety and Tolerability Study for the Pneumococcal Conjugate Vaccine V114 Versus Prevnar™ (V114-001) Phase 1
Completed NCT02892812 - A Phase I Clinical Trial of a 13-valent Pneumococcal Conjugate Vaccine and 14-valent Pneumococcal Conjugate Vaccine in Adults Phase 1
Completed NCT02116998 - Safety, Tolerability, and Efficacy Study of Prophylactic S. Pneumoniae Vaccine Following Challenge With S. Pneumoniae Phase 2
Completed NCT01446926 - Study of Investigational Pneumococcal Vaccine in Healthy Adults, Toddlers and Infants Phase 1
Completed NCT01193582 - A Study To Assess The Safety And Effectiveness Of Prevenar In Chinese Children Who Have Not Previously Received A Vaccine Against Pneumococcal Bacteria Phase 4
Completed NCT00744263 - Study Evaluating the Effiacy of a 13-Valent Pneumococcal Conjugate Vaccine (13vPnC) in Adults Phase 4
Completed NCT00492557 - Study Evaluating Safety and Immunogenicity of 13-Valent Pneumococcal Conjugate Vaccine With Influenza Vaccine in Adults Phase 3
Completed NCT00195611 - Study of Streptococcus Pneumoniae in Nose and Throats of Infants With Acute Otitis Media Phase 4
Completed NCT00137605 - Early Versus Delayed Pneumococcal Vaccination in HIV Phase 1/Phase 2
Completed NCT00205803 - Study Evaluating Pneumococcal Vaccine in Healthy Infants Phase 1/Phase 2
Completed NCT02531373 - A Study to Evaluate the Safety, Tolerability and Immunogenicity of V114 in Healthy Adults and Infants (V114-005) Phase 1/Phase 2
Completed NCT03615482 - A Study to Evaluate the Safety, Tolerability, and Immunogenicity of V114 When Administered Concomitantly With Influenza Vaccine in Healthy Adults 50 Years of Age or Older (V114-021/PNEU-FLU) Phase 3
Completed NCT03565900 - A Study to Evaluate the Safety, Tolerability, and Immunogenicity of V114 in Allogeneic Hematopoietic Stem Cell Transplant Recipients (V114-022/PNEU-STEM) Phase 3
Completed NCT04989465 - A Clinical Trial of 23-valent Pneumococcal Polysaccharide Vaccine Phase 4
Completed NCT02547649 - Safety, Tolerability, and Immunogenicity of Two Formulations of V114 in Healthy Adults 50 Years of Age or Older (V114-006) Phase 2
Completed NCT02573181 - Safety, Tolerability, and Immunogenicity of V114 Compared to Prevnar 13™ in PPSV23-vaccinated Healthy Adults ≥65 Years of Age (V114-007) Phase 2